Skip to main content

Posters

March 02, 2019
Background: Tardive dyskinesia (TD) is associated with antipsychotics. To date, predictive models assessing the clinical characteristics on TD risk have not been developed and validated in the US population. Objective: To develop a prediction model identifying factors associated with TD occurrence.
March 02, 2019
Background: In the 12-week ARM-TD and AIM-TD studies, the odds of response to deutetrabenazine treatment were higher than the odds of response to placebo at all response levels. Deutetrabenazine was associated with low rates of overall adverse events and discontinuation. Objective: To evaluate long…
March 02, 2019
Objective: To evaluate the long-term safety and tolerability of once-daily valbenazine in adults with tardive dyskinesia (TD).
March 02, 2019
Background: Tardive dyskinesia (TD) is a movement disorder that may intensify the stigma of patients with psychiatric disorders. In the ARM-TD and AIM-TD trials (parent studies), deutetrabenazine (DTB) significantly improved TD symptoms versus placebo and was well tolerated. Objective: To evaluate…
March 02, 2019
Objective: To evaluate the long-term safety and efficacy of lurasidone in children and adolescents with bipolar depression. Methods: Patients (10-17 years) with bipolar depression who completed 6 weeks of double-blind (DB), placebo-controlled treatment with lurasidone were enrolled in a 2-year,…
March 02, 2019
Background: Tardive dyskinesia (TD) is managed by dose reduction or interruption of dopamine-receptor antagonists (DRAs), possibly causing psychiatric disorder relapse. Deutetrabenazine (DTB) was efficacious and safe for the treatment of TD in the ARM-TD and AIM-TD trials regardless of baseline DRA…
March 02, 2019
Background: Long-acting injectable (LAI) antipsychotics have significant differences in formulation composition, which is an important factor for administration technique. Here, we review formulations of LAIs indicated for schizophrenia treatment and how they impact instructions for use, with a…
March 02, 2019
Objective: To evaluate the efficacy of lurasidone in treating pediatric patients with bipolar depression who presented with high levels of anxiety.
March 02, 2019
Introduction: We sought to determine whether continuing medical education (CME) improves knowledge regarding bipolar disorder (BPD) and its treatment with the use of long acting injectable antipsychotics (LAIs).
March 02, 2019
Objective: To document possible tardive dyskinesia (TD) in psychiatric outpatients, as assessed by patients, caregivers, and clinicians.
Back to Top